Tyra Biosciences is a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance. The company develops a proprietary SNÅP platform to identify and selectively target vulnerabilities in mutant proteins. Its product candidates include the FGFR3 program—TYRA-300, the FGFR2 program, as well as the achondroplasia, RET, and FGFR4 programs.